These results indicated that FUS-MB delivery system in combination with adjunct therapeutic strategies targeting immune checkpoints (such as PD-1, CTLA-4, and TIM-3) may improve the outcomes of anti-tumor therapy. The gene discussed is CTLA4; the disease is neoplasm.